Melanoma Patient Articles & Analysis
15 news found
The Merlin Test identifies melanoma patients that have a low risk for nodal metastasis and therefore can safely forgo a sentinel lymph node biopsy (SLNB) surgery. ...
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor growth inhibition ...
The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate, progression-free survival and overall survival in patients with advanced melanoma, who are also eligible for treatment with pembrolizumab. ...
ByScancell
The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation. ...
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, ...
This approval makes FoundationOne®CDx the only comprehensive genomic profiling (CGP) test approved as a companion diagnostic across two groups of targeted therapies, representing an important step toward simplifying decision making for oncologists. Melanoma is a serious form of skin cancer that accounts for an estimated 207,790 cases each year.1 BRAF mutations are the most ...
Details of the poster presentation: Title: Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL2-independent persistence and anti-tumor efficacy against melanoma in vivo Abstract Number: 166 Category: Cellular Therapy Abstract Summary: Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has demonstrated tremendous promise in clinical ...
Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expenses Data reported in early July 2021 from EVX-01 Phase 1/2a clinical trial showed a robust anti-tumor effect in combination with anti-PD-1 treatment for ...
Key clinical findings from IMA203 Phase 1a trial In the ongoing ACTengine® IMA203 trial, Immatics is treating advanced solid cancer patients utilizing TCR-T cells directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). ...
Details of the poster presentation: Title: cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility Abstract Number: 1008P Session: Investigational Immunotherapy Abstract Summary: Tumor-infiltrating lymphocytes (TILs) have generated promising data in ...
The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients. It has enabled the Company to identify the first microbiome signature predictive of response to ICI therapy across four independent melanoma studies, by analysing MELRESIST, a melanoma study conducted in collaboration ...
The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients. It has enabled the Company to identify the first microbiome signature predictive of response to ICI therapy across four independent melanoma studies, by analysing MELRESIST, a melanoma study conducted in collaboration ...
Details of the poster: Title: cytoTIL™ therapy engineered with mbIL15 demonstrates enhanced in vivo persistence in the absence of IL-2, paving the way for durable efficacy and improved safety in patients with solid tumor malignancies Abstract Number: 617 Session: Cancer – Immunotherapy, Cancer Vaccines Session Date and Time: Tuesday May 11, 2021 8:00 AM – ...
Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO COPENHAGEN, Denmark, April 06, 2021 ...
The San Francisco-based company has developed software tools for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of patients samples. According to the Y Combinator-backed firm, its software platform has reduced the cost of single-cell genomics by tenfold while providing scalability capable of ...
ByImmunai